Tilray Buys HelloMD Telehealth Platform in Court-Supervised Sale

One of Canada’s largest licensed producers has taken over the digital front door that steered hundreds of thousands of medical cannabis patients toward suppliers. Tilray Brands (TLRY ) has acquired HelloMD Corporation’s Canadian medical cannabis assets through a court-supervised sale, the company said on June 29, 2026, the same day the deal cleared court approval. Financial terms were not disclosed.

HelloMD ran as a telehealth platform, connecting patients with health-care practitioners who could authorize medical cannabis and then routing certified patients to licensed sellers. Tilray was the successful bidder in HelloMD’s formal sale process and folds the platform into its existing Canadian medical operation, giving the producer a direct line to patients it previously reached mainly through prescribers and provincial channels.

A distressed asset, absorbed

HelloMD changed hands through a court-supervised sale process — the route a distressed operator takes when creditors move to recover value and a buyer is chosen through formal bidding. Such sales typically transfer the assets to the winning bidder clear of most of the seller’s liabilities, an efficient way to pick up a built-out platform at a discount.

The move fits a pattern. Tilray has spent 2026 buying distressed operators with established networks: it bought the Scottish brewer BrewDog out of administration in March 2026 and folded in the UK’s Lyphe Clinic the following month. HelloMD is the Canadian entry in that run — a platform that built real patient reach but ended up in a court-run sale as the domestic medical market it served contracted. Distressed M&A has become the dominant mode of consolidation across Canadian cannabis, as capital-heavier producers absorb the networks of operators that legalization’s early boom left overbuilt.

Tilray, one of Canada’s original licensed producers and the owner of brands including Good Supply, Redecan and Broken Coast, frames the purchase as completing a fully vertically integrated medical cannabis framework in its home market — linking cultivation, clinical expertise, a practitioner network and national fulfilment under one roof. Blair MacNeil, president of Tilray Canada, said the combination creates “a more connected pathway for patients and healthcare practitioners in Canada.”

Doubling down on a shrinking channel

The strategic question is why a producer would deepen its bet on Canada’s medical channel at all. Since adult-use legalization in October 2018, recreational sales have absorbed most consumer demand, and the medical side has become the smaller, slower-growing part of the legal market.

The scale gap is stark. In December 2025, federally licensed sellers moved about 1.1 million packaged units to registered medical clients, against more than 25 million units of non-medical product, according to Health Canada — leaving the medical channel at roughly four percent of the packaged market. Producers have faced steady price and margin pressure as that channel narrowed.

Tilray’s answer is that owning the patient relationship, not just the product, is where the remaining value sits. HelloMD gives it an acquisition funnel — a way to reach eligible patients earlier through education and practitioner access rather than meeting them only at the point of sale. The company also flagged adjacent wellness categories such as sleep and pain management, where over-the-counter products form a far larger market than medical cannabis and where a patient-education platform could steer consumers toward regulated options.

Importing a European playbook

The integrated model is not new for Tilray — it is being brought home. The company already runs a network of medical clinics and digital pharmacies in Germany, distributes pharmaceutical product through its CC Pharma arm, and operates certified cultivation across a medical business that spans 20 countries. Its European push has carried the growth story while the domestic market stagnated.

That gap reflects a broader reality: Canada’s medical cannabis strength now sits largely in exports rather than in domestic patients. Canadian producers supply a growing share of medical markets abroad, and the UK’s fast-expanding import market is dominated by Canadian product. Rivals have leaned into the same international pivot — Rubicon Organics recently cleared its Cascadia line for export — as growth at home proves hard to find.

For Canadian patients, the immediate change is ownership: a widely used, independent platform now belongs to a major producer that also sells them cannabis. Tilray says it will keep HelloMD’s existing partnerships in place to maintain continuity of care. The larger test is whether folding the patient funnel, the clinical layer and the supply chain into one company can make a thinning medical channel pay — or whether it simply concentrates a shrinking market in fewer hands.